Jhanelle E Gray

List of Publications by Year
in descending order

20 papers	10,639 citations	687363 13 h-index	794594 19 g-index
20 all docs	20 docs citations	20 times ranked	11539 citing authors

#	Article	IF	Citations
1	Pembrolizumab plus Chemotherapy in Metastatic Nonâ€“Small-Cell Lung Cancer. New England Journal of Medicine, 2018, 378, 2078-2092.	27.0	4,701
2	Osimertinib in UntreatedEGFR-Mutated Advanced Nonâ€“Small-Cell Lung Cancer. New England Journal of Medicine, 2018, 378, 113-125.	27.0	3,530
3	Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC. New England Journal of Medicine, 2020, 382, 41-50.	27.0	1,725
4	Structure-based classification predicts drug response in EGFR-mutant NSCLC. Nature, 2021, 597, 732-737.	27.8	185
5	Strategies for the successful implementation of plasma-based NSCLC genotyping in clinical practice. Nature Reviews Clinical Oncology, 2021, 18, 56-62.	27.6	99
6	Phase I/Ib Study of Pembrolizumab Plus Vorinostat in Advanced/Metastatic Nonâ€“Small Cell Lung Cancer. Clinical Cancer Research, 2019, 25, 6623-6632.	7.0	96
7	Non-invasive measurement of PD-L1 status and prediction of immunotherapy response using deep learning of PET/CT images. , 2021, 9, e002118.		75
8	Postprogression Outcomes for Osimertinib versus Standard-of-Care EGFR-TKI in Patients with Previously Untreated EGFR-mutated Advanced Nonâ€“Small Cell Lung Cancer. Clinical Cancer Research, 2019, 25, 2058-2063.	7.0	52
9	Overall Treatment Strategy for Patients With Metastatic NSCLC With Activating EGFR Mutations. Clinical Lung Cancer, 2022, 23, e69-e82.	2.6	31
10	A retrospective observational study of the natural history of advanced nonâ€“small-cell lung cancer in patients with KRAS p.G12C mutated or wild-type disease. Lung Cancer, 2021, 159, 1-9.	2.0	28
11	HDAC inhibitors with PD-1 blockade: a promising strategy for treatment of multiple cancer types?. Epigenomics, 2016, 8, 1015-1017.	2.1	22
12	A phase I/randomized phase II study of GM.CD40L vaccine in combination with CCL21 in patients with advanced lung adenocarcinoma. Cancer Immunology, Immunotherapy, 2018, 67, 1853-1862.	4.2	21
13	Immunotherapy combination strategies (non-chemotherapy) in non-small cell lung cancer. Journal of Thoracic Disease, 2018, 10, S433-S450.	1.4	15
14	Plasma Cell-Free DNA Genotyping: From an Emerging Concept to a Standard-of-Care Tool in Metastatic Non-Small Cell Lung Cancer. Oncologist, 2021, 26, e1812-e1821.	3.7	15
15	Phase 2 Study of Concurrent Cetuximab Plus Definitive Thoracic Radiation Therapy Followed by Consolidation Docetaxel Plus Cetuximab in Poor Prognosis or Elderly Patients With Locally Advanced Non-Small Cell Lung Cancer. International Journal of Radiation Oncology Biology Physics, 2014, 90, 828-833.	0.8	11
16	Integration of immunotherapy into adjuvant therapy for resected non-small-cell lung cancer: ALCHEMIST chemo-IO (ACCIO). Immunotherapy, 2021, 13, 727-734.	2.0	11
17	BRAF V600E mutations: a series of case reports in patients with nonâ€“small cell lung cancer. Cancer Genetics, 2015, 208, 351-354.	0.4	9
18	RNA splicing and aggregate gene expression differences in lung squamous cell carcinoma between patients of West African and European ancestry. Lung Cancer, 2021, 153, 90-98.	2.0	6

#	Article	IF	Citations
19	Pathology Issues in Thoracic Oncology: Histologic Characterization and Tissue/Plasma Genotyping May Resolve Diagnostic Dilemmas. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2017, 37, 619-629.	3.8	4
20	Biomarkers of therapeutic response with immune checkpoint inhibitors. Annals of Translational Medicine, 2021, 9, 1040-1040.	1.7	3